GlaxoSmithKline Intellectual Property Development

Part of GSK

Company

GlaxoSmithKline Intellectual Property Development develops 2 assets, the furthest in phase 3, no development reported (sotrovimab in COVID-19). Mostly antibody acting on S.

2
Assets
Furthest stage
Phase 3, no development reported
0
Trials
0
Signals

Pipeline

2
  • sotrovimab

    Monoclonal antibody engineered for immune engagement.

    Phase 3, no development reported, Antibody, S, COVID-19, Partner

  • beludavimab

    Binds SARS-CoV-2 spike protein to neutralize the virus, with an engineered Fc region enhancing immune effector functions.

    Preclinical, no development reported, Antibody, COVID-19, Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals4
  • Similar companies6

Intelligence